Home
Discover
Trends
Leaders
Trending Assets
Top investors this month
Trending Assets
Top investors this month
@cams_report
Cams Report
Always apply mathematical/quantitative methods when evaluating financial products or markets relating to portions of quantity of another🎤LIVE CHANNEL 🎥
1 following8 followers
PortfolioPostsCommentsTradesWatchlist
Cams Report's avatar
Cams Report
@cams_report12/19/2022
Madrigal Pharmaceuticals Up 268.07%
$MDGL up big - Madrigal Stock Triples After Liver Disease Drug Succeeds in Trial
(Bloomberg) -- Madrigal Pharmaceuticals Inc. shares surged 268%, adding about $2.9 billion to its market value, after a late-stage clinical trial of its drug candidate met the main goals in patients with a type of liver disease.
Ben
@rpinvestments12/20/2022
Finally. A successful stage 3 NASH tx.

obeticholic acid
Intercept Pharma’s drug.
Genfits- Elafibranor in 2021
Bristol Meyers Squib - pegbelfermin
NGM Biopharmaceuticals drug
Horizon Therapuetics

ALL failed…

Background
Current leading cause of liver fibrosis is Hepatitis C (a chronic viral infection). But since Gilead and others effectively cured Hep C. The future leading cause of liver fibrosis will be NASH - non-alcoholic steatohepatitis.

This is when excess fat is stored in the liver -> with time can cause liver scarring -> fibrosis-> cirrhosis and failure or cancer.

image
Madrigal media release looks great on the surface. I’ll have to ready the actual study to be sure.
+ 1 comment
Watchlist
Something went wrong while loading your statistics.
Please try again later.
Already have an account?